EP
MDGL icon

Eversept Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Eversept Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,000
Closed -$5.23M – 138
2026
Q1 		$5.23M Buy
+10,000
New +$4.78M 0.28% 58
2018
Q4 		– Sell
-9,400
Closed -$2.01M – 60
2018
Q3 		$2.01M Buy
9,400
+4,900
+109% +$1.23M 0.88% 21
2018
Q2 		$1.26M Buy
+4,500
New +$790K 0.58% 38

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eversept Partners's MDGL Position: Q2 2026 in Review

Eversept Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 10,000 shares — an estimated $5.23M sold.

Eversept Partners first reported a position in MDGL in Q2 2018 and held it in 3 quarters. The position peaked at $5.23M in Q1 2026. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Eversept Partners reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Eversept Partners sold 10,000 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $5.23M.
  • Eversept Partners first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Eversept Partners's Madrigal Pharmaceuticals position peaked at $5.23M in Q1 2026.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.